INTRODUCTION {#S1}
============

Within the past decade, tremendous efforts have focused on systematic, genome-wide surveys to identify the most frequently modified genes to distinguish those that drive carcinogenesis from those that are modified because of generalized genomic instability. Results from these tumor sequencing studies indicate that many cancers harbor alterations in only 3--4 known drivers, and 15% of tumors lack alterations in even a single known driver ([@R12]; [@R22]; [@R36]). In addition, solid tumors arise because of oncogenic cooperation between alterations of multiple drivers ([@R19]; [@R26]). These considerations strongly suggest that there are many drivers yet to be identified that are altered at low frequencies in cancer ([@R2]; [@R40]; [@R51]; [@R54]; [@R88]). Although these long tail (LT) driver genes are difficult to identify because they are mutated at frequencies only slightly greater than those for passenger genes, knowledge of how they affect major signaling pathways controlling growth and proliferation is critical for understanding and treating cancer based on its genetic underpinnings.

It has been challenging to identify cooperating cancer genes (CCGs) from analysis of existing collections of tumor sequence data. They are underpowered because of the relatively few tumors for many tumor types ([@R2]; [@R40]; [@R51]; [@R54]; [@R88]). In addition, extreme levels of tissue-specificity exist with respect to drivers of cell proliferation and survival regulation in cells ([@R25]; [@R76]; [@R78]); therefore, the precise tissue of interest must be examined in the organism of interest. Because of this, functional approaches, such as insertional mutagenesis, using transposon-based screens in mice, have been used to identify CCGs. For example, genes that may cooperate with *PTEN*, *SMAD4*, or *BRAF* for tumorigenesis have been identified with Sleeping Beauty or piggyBac mutator systems ([@R65]; [@R13]; [@R86]). However, for breast cancer, mouse and human tissues differ markedly in their genetic requirements for transformation ([@R71]), which has limited the extent to which insertional mutagenesis studies directly model human breast cancer and can be used functionally identify CCGs. A method to functionally identify cooperating genetic lesions in human breast cancers is needed. Therefore, we have developed a combinatorial loss-of-function screen to identify putative tumor suppressor genes (TSGs) whose cooperation is selected for by promoting tumorigenesis *in vivo*. We show that a top hit, *FUBP1*, is an LT gene that cooperates with *PTEN* as a powerful driver of neoplastic transformation. Furthermore, via regulation of RNA N^6^-methyladenosine (m^6^A) methylation, FUBP1 globally affects the landscape of alternative splicing to create aberrant proteins that drive malignant transformation.

RESULTS {#S2}
=======

Identification of Cooperating TSGs in an *In vivo* Loss-of-Function CRISPR-Cas9 Screen {#S3}
--------------------------------------------------------------------------------------

We created a unique resource to screen for functionally relevant LT drivers in an unbiased manner: a small genetic library targeting genes that are clinically altered in cancer and thus strongly enriched for high-priority candidates. For loss-of-function screening, a "TSG" library, comprising the 500 genes that are most significantly affected by loss of function in human cancers according to the Tumor Suppressor and Oncogene (TUSON) Explorer algorithm ([@R12]) in a lentiviral CRISPR-Cas9 format, was developed. This library has already been used in conjunction with an oncogene open reading frame (ORF) library to investigate how cancer drivers interact in an *in vitro* screen, revealing a spectrum of TSGs and oncogenes that can genetically interact and substitute for one another to modify the behavior of cancer cells with disrupted EGFR signaling ([@R48]). Additionally, the same libraries have been used *in vitro* to identify TSGs and oncogenes that may similarly substitute for BRD4-NUT, the complex of an epigenetic factor BRD4 and the protein NUT that cause oncogenic signaling and tumor growth, particularly in NUT midline carcinoma ([@R49]).

To screen for preferentially cooperating LT drivers, we created a sub-library of 100 TSGs with 10 single guide RNAs (sgRNAs) per each targeted gene ([Figure 1A](#F1){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). MCF10F cells (immortalized, non-transformed human mammary epithelial cells) were transduced with the pooled library at a multiplicity of infection (MOI) of 3, to ensure that most cells received at least two sgRNAs. This strategy enabled us to interrogate approximately 1 × 10^6^ different sgRNA combinations, targeting an average of three putative TSGs in each cell. Infected cells were orthotopically implanted into the inguinal mammary glands of immunocompromised non-obese diabetic/and severe combined immunodeficiency (NOD-SCID) mice and monitored for tumor growth. All mice developed tumors, and tumors larger than 5 cm^3^ were randomly sampled for histology, whereas the remainder of the tumor was sequenced. Numerous growth patterns were observed within and across the H&E-stained tumors, including squamous, metaplastic, and papillary carcinomas ([Figure 1B](#F1){ref-type="fig"}). We also detected variable expression of biomarkers and hormone-receptor expression common in human tumors, recapitulating clinical presentations of heterogeneous human breast cancers ([Figures 1C](#F1){ref-type="fig"} and [S1](#SD1){ref-type="supplementary-material"}). This intra- and inter-tumor heterogeneity mirrors clinical cancers and is consistent with different combinations of genetic drivers influencing tumor phenotype ([@R53]).

Sequencing the recovered sgRNAs from the tumors' genomic DNA revealed that the tumors were clonally diverse and identified expected as well as unexpected CCGs ([Figure 1D](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). We noted that well-established cancer drivers clinically validated by sequencing of patient breast cancers (PTEN, RB, p53, NF2, SMAD4, *WT1*, *RUNX1*, *GATA3*, *MAP3K1*, *MLLT4*, *NCOR1*) cooperated with genes that have yet to be shown to be functional cancer drivers (*FUBP1*, *TRIP12*, *KDM5C*, *ARID1B*) in the breast. Among the unexpected CCGs, far upstream binding protein 1 (*FUBP1*), a gene previously uncharacterized in breast cancer, was a recurring hit in multiple breast tumors and appeared to cooperate with multiple established drivers (*PTEN*, *RB*, *p53*). Given its stark contribution to tumor formation in the screen and its understudied role in breast cancer, we focused on elucidating the role of *FUBP1* as an LT driver and how concurrent deletion of *PTEN* may enhance its role in cancer.

To examine the clinical relevance of concurrent loss of *FUBP1* and *PTEN*, as well as other CCGs from the screen, we interrogated public tumor datasets ([@R8]; [@R21]). We found that *FUBP1* alterations tend to significantly (p \< 0.001) co-occur with *PTEN* alterations, as well as alterations in *RB1*, *TP53*, *CDH1*, and *KDM5C*, across many cancer types, including glioblastoma and lung squamous cell carcinoma, as well as breast-invasive carcinoma ([Figure 1E](#F1){ref-type="fig"}). These correlations lend further validity to the screen as a method of identifying TSGs that preferentially cooperate to drive cancer.

FUBP1 is a single-stranded DNA and RNA-binding protein best known for its role as a positive regulator of *c-MYC* in normal hematopoiesis ([@R18]; [@R103]). FUBP1 is also a regulator of post-transcriptional events, such as translation, mRNA stability, and splicing ([@R35]; [@R38]; [@R101]). FUBP1 has been isolated in association with spliceosomal complexes ([@R35]; [@R37]; [@R38]; [@R47]; [@R50]; [@R61]) and includes four K homology domains, which are homologous to heterogeneous nuclear ribonucleoprotein K, a component of the spliceosomal H complexes ([@R3]; [@R5]). Its role in splicing has only recently begun to be understood. Depending on context, FUBP1 can either enhance or suppress splicing ([@R35]; [@R38]; [@R47]). In patients, *FUBP1* missense, nonsense, and silent mutations, as well as whole-gene deletions, frameshift deletions, and insertions are observed in cancers, such as those of the central nervous system and intestinal cancer ([@R2]; [@R4]; [@R52]; [@R74]; [@R77]; [@R82]; [@R102]). Despite the biochemical roles of FUBP1, it is unclear how its alteration may affect transformation or cancer pathogenesis.

*FUBP1* Loss Drives Several Characteristic Features of Transformation and Cooperates with *PTEN* Loss to Promote Tumor Growth *In vivo* {#S4}
---------------------------------------------------------------------------------------------------------------------------------------

We used CRISPR-Cas9 to generate *FUBP1-*, *PTEN-*, and *PTEN*/*FUBP1-*null MCF10F cells using two different sgRNAs targeting *FUBP1* to assess how loss of the genes individually or in combination might affect features of transformation. Western blot analysis validated complete loss of *FUBP1* and/or *PTEN* in MCF10F cells ([Figures 2A](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). Loss of *FUBP1* or *PTEN* alone or in combination significantly increased cellular proliferation compared with the non-targeting control (NTC) ([Figures 2B](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). Although there was occasional colony formation of *PTEN* null cells on soft agar, loss of *FUBP1* in combination with *PTEN* led to the most significant increase in anchorage-independent colony formation on soft agar ([Figures 2C](#F2){ref-type="fig"}, [2D](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}).

Because loss of tissue architecture is a hallmark of transformation, we seeded cells in 3D hydrogels to assess the role of *FUBP1* on tissue morphogenesis and differentiation. *FUBP1*-, *PTEN*-, and *PTEN*/*FUBP1-*null MCF10F cells were grown in collagen-based hydrogels ([@R60]; [@R83]) supplemented with extracellular matrix components and allowed to grow for 10 days ([Figures 2E](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). In this assay, the cells grew into different types of 3D tissues with varying degrees of structural complexity. We classified the growths based on morphology, presence of CK14^+^ basal and CK8/18^+^ luminal mammary epithelial cells, and integrity of cellular polarity (basal cells surrounding luminal cells). The 3D outgrowths were classified into the following morphologically distinct groups: normal glandular tissue with conserved organization of cells (T1), normal structure but loss of polarity (T2), disrupted structure and loss of either basal cells or luminal cells (T3), and complete loss of structure with significantly diminished numbers of basal cells (T4) ([Figures 2E](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). We found that most control cells grow as normal T1 and T2 structures, whereas the loss of *PTEN*, *FUBP1*, or the combination of *PTEN*/*FUBP1* caused a significant increase in the number of abnormal T3 and T4 structures. *PTEN* loss led to the preferential formation of T3 structures, whereas *FUBP1* loss alone or in combination with *PTEN* was associated with the development of disrupted T4 structures ([Figures 2E](#F2){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). Thus, *FUBP1* loss affected 3D tissue organization, basal differentiation, and cellular polarity, including a significant loss of basal cells.

To determine whether loss of *FUBP1* alone or combined with the loss of *PTEN* promotes tumorigenic behavior *in vivo*, *FUBP1-*, *PTEN-*, or *FUBP1*/*PTEN-*null MCF10F cells were implanted into the inguinal mammary glands of NOD-SCID mice. Within 2 weeks, all mice implanted with *FUBP1*/*PTEN-*deficient cells had formed tumors, whereas *FUBP1-*null or *PTEN-*null cells did not ([Figures 2F](#F2){ref-type="fig"} and [2G](#F2){ref-type="fig"}). Gross and microscopic examination of the *PTEN*/*FUBP1-*deficient tumors revealed expansive, angiogenic, cystic tumors containing widespread inflammation and abnormal mitoses ([Figure 2H](#F2){ref-type="fig"}). Collectively, these findings demonstrate that cells with the loss of *FUBP1* alone and in combination with *PTEN* exhibit classic hallmarks of transformation, including increased proliferation, anchorage-independent growth, and loss of tissue architecture, and they form tumors *in vivo*.

*FUBP1* Loss Causes Widespread Alternative Splicing and Processing of Cancer Driver Genes {#S5}
-----------------------------------------------------------------------------------------

To determine how *FUPB1* loss contributes to neoplastic transformation, gene expression profiling was performed by RNA sequencing (RNA-seq) in cells deficient for *FUBP1* ([Figure S3](#SD1){ref-type="supplementary-material"}). There were a number of differentially expressed genes between the *FUBP1-*null and NTC cells, \~25% of which were noncoding RNA transcripts (ncRNA). Gene set enrichment analysis (GSEA) of differentially expressed genes revealed a strong negative enrichment for the epithelial-to-mesenchymal transition (EMT)-related genes (*TGFB1*, *SNAI2*, *MFAP5*), consistent with the loss of basal cells in *FUBP1-*null cells. Given previous findings showing that FUBP1 can promote *MYC* activation ([@R18]; [@R28]), we also examined whether *FUBP1* deficiency might be affecting *MYC* expression and/or downstream *MYC* signaling. However, consistent with a recent report ([@R80]), we did not see a significant reduction in *MYC* expression levels in cells lacking *FUBP1*.

Accumulating evidence shows that alternative splicing has a key role in cancer pathogenesis; we and others ([@R41]; [@R64]) have shown that that mRNA splicing and processing creates genes and proteins that act as functional cancer drivers. Given that previous work has implicated *FUBP1* as a splicing regulator ([@R35]; [@R38]), we were interested in determining whether *FUBP1* loss might be affecting alternative splicing and processing (AS) events that would be leading to upregulation of variant mRNA transcripts. Applying replicative multivariate analysis of splicing (rMATS 4.0.1) to the RNA-seq data, we found more than 10,000 differential AS events between the NTC and *FUBP1-*null MCF10F cells, \~60% of which are unannotated splicing events. Across the differential splice events, 70% were skipped exons (SEs), 16% mutually exclusive exons (MXEs), 7% alternative 3′-splice sites (A3SS), 6% alternative 5′-splice sites (A5SS), and 1% retained intron events (RIs) ([Figure 3A](#F3){ref-type="fig"}). We used the Database for Annotation, Visualization, and Integrated Discovery (DAVID) ([@R31], [@R32]) to functionally cluster the AS transcripts most significantly expressed differentially to begin to understand the global consequences of these AS events. Many of the alternatively spliced genes in *FUBP1-*null cells were involved in mRNA processing, cell cycle, and DNA damage repair ([Figure 3B](#F3){ref-type="fig"}), which might signal potential vulnerabilities of tumors bearing *FUBP1* mutations.

There is increasing interest in understanding how mRNA events, such as AS, can be as potent as DNA mutation events in driving tumorigenesis. In human breast cancer and chronic lymphocytic leukemia (CLL), recurrent, truncated mRNAs caused by intronic polyadenylation affect genes with tumor-suppressive functions and can give rise to oncoproteins ([@R41]; [@R64]; [@R66]). In *FUBP1-*null cells, 11 genes with tumor-suppressive functions were found to be truncated by AS ([Figure 3C](#F3){ref-type="fig"}). Three FUBP1 AS targets were the same recurrent variants found in human CLL: *DICER*, *MGA*, and *ZMYM5* ([@R41]) ([Figures S4A](#SD1){ref-type="supplementary-material"}--[S4C](#SD1){ref-type="supplementary-material"}). Our analyses revealed that 11% of DICER1 transcripts, 61.5% of MGA transcripts, and 28.5% of ZMYM5 transcripts undergo AS to generate aberrantly A3′-spliced isoforms. The prematurely truncated form of *DICER1* encodes for a protein that is unable to process microRNA (miRNA), leading to reduced functional DICER protein and altered miRNA processing ([@R41]). The prematurely truncated form of *MGA* creates a dominant-negative regulator of full-length MGA to act as an oncoprotein ([@R41]). Additionally, in concordance with previous reports showing that FUBP1 acts as a splicing regulatory factor for the oncogene MDM2, we also detected that *FUBP1-*null cells exhibit AS of *MDM2*, leading to a 4-fold increase in the expression of MDM2-ALT2, an alternative variant reported to increase cyclin D1 to promote malignancy ([@R38]) ([Figure S4D](#SD1){ref-type="supplementary-material"}). Other FUBP1 targets include Caspase8 (*CASP8*), which undergoes alternative A3′ splicing, resulting in a non-functional transcript ([Figure 3D](#F3){ref-type="fig"}). CASP8 is an important regulator of apoptosis, and the loss of functional CASP8 may result in a classic hallmark of cancer, evasion of apoptosis ([@R84]). Western blotting for CASP8 revealed a complete loss of CASP8 protein in *FUBP1-*null cells, and the corresponding Sashimi plot shows that, although there are 18 raw junction read counts for the A3′-spliced CASP8 transcript in the *FUBP1-*null samples, there are only four in the NTC ([Figure 3D](#F3){ref-type="fig"}).

FUBP1 also targets the tumor suppressor *BRCA1*, a gene notoriously linked to breast and ovarian cancers ([Figure 3E](#F3){ref-type="fig"}). *FUBP1-*null cells strongly overexpress a *BRCA1* variant, BRCA1^Δ11b^, which lacks most of exon 11, the large internal exon that contains the nuclear localization signal (NLS) and the RAD51 binding domain, and it is the mutational hotspot in a large fraction of *BRCA1* mutation carriers ([@R59]; [@R93]). Previous work has shown that BRCA1^Δ11b^-expressing cells have diminished double-stranded break repair ([@R33]; [@R92]). We used immunoblotting to validate that the \~100-kDa BRCA1^Δ11b^ is expressed in the *FUBP1-*null, but not the NTC, cells.

Additionally, the oncogenic, prematurely truncated *MAGI3* transcript *MAGI3*^*pPA*^ is strongly expressed in the *FUBP1-*null, but not the NTC, cells ([Figure 3F](#F3){ref-type="fig"}). The full-length MAGI3^FL^ is a TSG and a regulator of the Hippo signaling pathway that normally binds and inactivates YAP to prevent tissue overgrowth and other behaviors characteristic of cancer ([@R64]). The prematurely truncated form, MAGI3^pPA^, is unable to bind YAP, thus promoting classic oncogenic behavior ([@R64]). Validation of CASP8, MAGI3, and BRCA1 AS events was also performed with *FUBP1-*null cells generated with an alternative sgRNA, confirming those changes were not off-target events ([Figures S2F](#SD1){ref-type="supplementary-material"}--[S2H](#SD1){ref-type="supplementary-material"}).

We also assessed the effects of *FUBP1* loss on AS in an additional nontumorigenic mammary epithelial cell line, MCF10A ([Figure S5A](#SD1){ref-type="supplementary-material"}). Similar to the *FUBP1-*null MCF10F cells, *FUBP1-*null MCF10A cells showed a complete loss of CASP8 protein, compared with the NTC ([Figure S5B](#SD1){ref-type="supplementary-material"}). Unlike the MCF10F cells, however, the *FUBP1-*null MCF10A cells showed no difference in protein expression or splicing of MAGI3 or BRCA1 ([Figures S5C](#SD1){ref-type="supplementary-material"} and [S5D](#SD1){ref-type="supplementary-material"}). Interestingly, the NTC MCF10A cells exhibited a striking baseline expression of the aberrant isoforms MAGI3^pPA^ and BRCA1^Δ11b^. This may be because the MCF10A cell line is more stem-like ([@R73]) or perhaps because they already contain mutations in other genes that are important for splicing regulation.

To further expand our investigation beyond the mammary epithelium, we surveyed splicing data from cancers that harbor *FUBP1* loss-of-function (LoF) mutations as well as splicing changes in the human glioma cell line U87MG, in which FUBP1 was inhibited with small interfering RNA (siRNA) ([@R80]). We found an overlap of FUBP1 splicing targets in primary human brain cancers as well as in FUBP1-knockdown U87MG cells with *FUBP1-*null MCF10F. Of the 307 conserved alternatively spliced genes between the *FUBP1*-null MCF10F cells, primary glioma samples and siFUBP1 U87MG cells, 26 were significant ([Table 2](#T2){ref-type="table"}). Several of those overlapping genes were A3SS, A5SS, and SE splicing events (false discovery rate \[FDR\] \< 0.05). Taken together, these results support FUBP1 as an important regulator of AS and indicate that FUBP1 targets include cancer genes that are truncated or otherwise altered to drive malignant transformation.

*FUBP1* Loss Leads to a Reduction in m^6^A Modification Upstream of FUBP1-Regulated Splice Sites {#S6}
------------------------------------------------------------------------------------------------

To further investigate the mechanism by which FUBP1 controls AS events, we next performed co-immunoprecipitation (coIP) of V5-tagged FUBP1 followed by mass spectrometry (MS) to identify binding partners of FUBP1 that may participate in the regulation of mRNA processing ([Table S2](#SD3){ref-type="supplementary-material"}). We found significant enrichment for proteins involved in RNA splicing, mRNA processing and transport, as well as other regulators of translation (p ≤ 0.01) ([Figure S6A](#SD1){ref-type="supplementary-material"}; [Table S3](#SD4){ref-type="supplementary-material"}) with clusterProfiler ([@R98]) on the proteins that uniquely co-immunoprecipitated with FUBP1. This is consistent with previous reports of FUBP1 as a nucleic acid-binding protein and regulator of AS ([@R35]; [@R38]; [@R47]; [@R61]).

Among the set of FUBP1-interacting proteins identified by coIP/MS, we also identified several regulators of the mRNA methylation modification m^6^A, including RBM15, IGF2BP1, hnRNPA2B1, and VIRMA ([Figure S6B](#SD1){ref-type="supplementary-material"}). RNA binding motif 15 (RBM15) has been implicated as an RNA-binding protein that is involved with m^6^A machinery important in recruiting m^6^A core catalytic proteins ([@R69]). Protein Virilizer Homolog (VIRMA) is similarly a key component of the m^6^A methyltransferase that has a role in recruiting the core catalytic components METTL3, METTL14, and WTAP ([@R100]). We confirmed the presence of a protein-protein interaction between RBM15 and VIRMA, as well as other members of the m^6^A reactome with FUBP1 ([Figure 4A](#F4){ref-type="fig"}). We additionally probed for the m^6^A methyltransferase (methyltransferase-like protein 3 \[METTL3\]), and found that it co-immunoprecipitates with V5-tagged FUBP1, although not as strongly as with RBM15 and VIRMA ([Figure 4A](#F4){ref-type="fig"}). Given these findings, we hypothesized that FUBP1 recruits RBM15 and/or VIRMA, which then recruit METTL3 to form the methyltransferase complex that ultimately methylates target mRNA sites.

To determine whether expression of FUBP1 affects mRNA m^6^A levels, we performed dot-blot assays with mRNA from NTC and FUBP1-null cells. Interestingly, we found that loss of FUBP1 results in a modest, but reproducible, decrease in global m^6^A-modified mRNA, compared with the NTC ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Given that finding, we next investigated whether FUBP1 might also be recognizing and binding m^6^A-modified mRNA. We performed immunoprecipitations with biotinylated RNA baits with or without m^6^A modification, followed by probing for FUBP1 as well as a bona fide m^6^A-binding protein, YTHDF2 ([@R90]). Our results show that FUBP1 binds to both m^6^A-methylated and non-methylated RNAs ([Figure 4D](#F4){ref-type="fig"}), suggesting that FUBP1 may participate in bringing the m^6^A machinery to its intended site to promote methylation, but not that FUBP1 is specifically recognizing and binding methylated sites.

Given these findings, we next investigated whether FUBP1 acts as an m^6^A effector of AS. Recently, we reported that m^6^A has a role in regulating the formation of AS isoforms of various TSGs, including *MAGI3*, *BRCA1*, and *LATS1* ([@R66]). If FUBP1 is acting as an m^6^A effector of AS, then m^6^A marks might be enriched within large internal exons of the FUBP1 splicing targets. To test that, we analyzed an available transcriptome-wide m^6^A-sequencing dataset (GEO Database: GSE37005) generated in the human hepatocellular carcinoma HepG2 cell line to identify enrichment of m^6^A peaks in exons upstream of splice sites in FUBP1-regulated transcripts ([@R17]). We indeed found a concordance between m^6^A peak and splice-site localization ([Figures 4E](#F4){ref-type="fig"} and [S7](#SD1){ref-type="supplementary-material"}). We found significant enrichment for m^6^A in exon 8 of *CASP8*, upstream of the splice site that results in the formation of the non-coding *CASP8* transcript upregulated in *FUBP1-*null cells. Examination of m^6^A-seq peaks in *BRCA1* also revealed strong enrichment in exon 10, upstream of exon 11, which is skipped in the BRCA1^Δ11b^ isoform. There was also a strong m^6^A signal in exon 10 of *MAGI3*, which we previously showed to be related to the formation of the oncogenic, truncated MAGI3^pPA^ ([@R66]). Given that *FUBP1-*null cells exhibit a global decrease in m^6^A deposition and increased AS, these data suggest that it is possible that the same splice variants affected by *FUBP1* loss may be regulated by m^6^A deposition in exons directly upstream of their splice sites.

To investigate whether the splice variants affected by *FUBP1* loss are indeed regulated by m^6^A modifications in exons upstream of their splice sites, we used an m^6^A antibody and *FUBP1-*null MCF10F cells. Relative methylation levels of exons upstream of FUBP1-regulated splice sites were determined by quantitative real-time PCR ([Figure 4F](#F4){ref-type="fig"}). We found significantly decreased m^6^A methylation levels in two m^6^A consensus sites in exon 8 of *CASP8*, two m^6^A sites in exon 10 of *BRCA1*, and two m^6^A sites in exon 10 of *MAGI3* in *FUBP1-*null cells, compared with the NTC cells. Additionally, we performed quantitative real-time PCR on total RNA from NTC and *FUBP1-*null cells with primers flanking regions without m^6^A sites that were distal from the exons of interest for each gene ([Figure 4G](#F4){ref-type="fig"}). We detected that the NTC and *FUBP1-*null cells did not express significantly different levels of *CASP8*, *BRCA1*, or *MAGI3* mRNA, indicating that the decreases in m^6^A in the exons upstream of the splice sites of interest were not simply due to a decrease in expression of the genes overall. Altogether, these data suggest that the loss of *FUBP1* results in decreased m^6^A in regions that may be important for the regulation of mRNA splicing. Further work to examine how inhibiting or genetically deleting other components of the m^6^A complex affects the splicing of these and other genes is warranted to solidify the significance of these proteins in AS.

FUBP1 and Other m^6^A-Associated Proteins Are Altered in Human Breast Cancers {#S7}
-----------------------------------------------------------------------------

We next assessed the mutational frequency and copy number variations (CNVs) of *FUBP1* in \~3,000 human breast cancer clinical samples using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset, generated from a long-term study of 2,509 breast tumors and 548 matched normal samples ([@R8]; [@R21]; [@R70]). Not surprisingly, \~6% of human breast tumors assessed have alterations in *FUBP1*, in concordance with the low alteration rate of LT drivers ([Figure 5A](#F5){ref-type="fig"}). We found that, in contrast to canonical drivers like *PTEN*, which are mostly affected by deep deletions in cancer, *FUBP1* alterations in these breast tumor samples include a range of alterations, including amplifications, as well as decreased mRNA levels. This may be due to the multiple roles *FUBP1* has been shown to have in cancer, ranging from both activating *MYC* and negatively regulating its expression ([@R30]) to participating in a variety of post-transcriptional events.

Since our findings suggest that FUBP1 contributes to tumorigenicity by participating in m^6^A RNA methylation to regulate AS, we speculated that other genes involved in this modification might also be altered in breast cancer. Thus, we examined the frequency of mRNA and CNVs in FUBP1 binding partners as well as other m^6^A regulators ([Figure 5B](#F5){ref-type="fig"}). *VIRMA* has copy number or significant changes to mRNA levels in more than 20% of the human breast tumors assessed, whereas other FUBP1 binding partners, *RBM15* and *IGFBP2*, are altered in breast cancers at frequencies similar to FUBP1. Given those findings, we extended the analysis to other m^6^A modifiers. Indeed, alterations in other m^6^A readers, writers, and erasers are present in breast cancer at frequencies similar to *FUBP1*, suggesting they too may represent LT drivers. Like *FUBP1*, these genes undergo both amplifications and deep deletions, suggesting that their alteration in either direction may alter a homeostatic balance needed for the complex to function properly. The significance of such alterations in these m^6^A regulators will require further investigation to determine the extent of their contribution to malignant transformation. Cumulatively, however, these data reveal that alterations in the effectors of the m^6^A modification are clinically relevant in human breast cancers, strongly supporting the theory that disrupting this process is a key driver of human breast cancer.

DISCUSSION {#S8}
==========

Tumor sequencing studies have enabled the identification of the most potent drivers of cancer, which have been the focus of intense study and represent major therapeutic targets in cancer medicine. The strategies used to discover these drivers are limited, however, because they focus on identifying genes based on their frequency of alteration. Here, we set out to discover understudied, less-frequently mutated drivers, which have been referred to as the "long tail" cancer drivers ([@R1]; [@R9]; [@R42]; [@R94]). We employed an unbiased combinatorial screen for preferentially CCGs in a mouse xenograft model of breast cancer using a TSG sgRNA library at a high MOI to ensure multiple alterations per cell. This created an environment in which cells with multiple genetic alterations competed for clonal dominance *in vivo* after orthotopic implantation into murine inguinal fat pads. This study uncovered multiple TSGs that showed genetic cooperativity with drivers such as *PTEN*, including *FUBP1*, a regulator of RNA modification and alternative splicing that affected multiple cancer-driver genes.

RNA splicing presents an opportunity for the expression of differentially configured transcripts that may be exploited by the cell to affect proliferation and survival. Examples of the dysregulation of splicing from cancer-promoting mutations in splicing factors, such as SF3B1 ([@R6]; [@R10]; [@R80]; [@R89]), has captured the attention of the cancer researchers and brought the role of splicing in cancer to the forefront of cancer research. Modifications of mRNA with the potential to influence splicing patterns are also gaining attention. Research on the most abundant RNA modification, m^6^A, has intensified in the past decade ([@R17]; [@R55], [@R56]; [@R58]). The effect of m^6^A levels on translation, degradation, and AS is far-reaching and has consequences in processes ranging from circadian rhythms to cancer ([@R11]; [@R20]; [@R27]; [@R39]; [@R67]). Most frequently found in large internal exons and the 3′ UTR, the m^6^A marks are well positioned for regulating alternative polyadenylation and AS ([@R57]). There have been specific examples of m^6^A binding proteins directly regulating splicing. For instance, through association with SRSF3 and SRSF10, YTHDC1 binds m^6^A-modified mRNA to influence AS ([@R95]). In addition, we have previously shown that reduced m^6^A marks are associated with the shortening of the MAGI3 ([@R66]).

In this study, we discovered *FUBP1* among the most significant hits in the screen in cooperation with other TSGs, most frequently *PTEN*. We validated that loss of *FUBP1*, alone and in combination with *PTEN*, promotes classic malignant phenotypes, including hyperproliferation, anchorage-independent growth, and alteration of 3D tissue architecture. Furthermore, concurrent loss of *PTEN* and *FUBP1* induced *in vivo* tumor growth. Analysis of human tumor datasets across many cancer types revealed that *FUBP1* significantly co-occurs with *PTEN* as do the other *PTEN* cooperating genes from our screen, further validating our genetic approach.

We found that loss of *FUBP1* resulted in the generation of \~10,000 AS events affecting a variety of cancer-related genes, such as *BRCA1*, *MAGI3*, *CASP8*. The FUBP1-regulated spliced form of *BRCA1*, *BRCA1*^*Δ11b*^, is missing most of exon 11 ([@R75]; [@R87]; [@R91]), an alternatively spliced isoform that results in the functional loss of BRCA1. Therefore, creating this variant has significant implications for DNA repair, accumulation of mutational burden, and potential therapeutic approaches, such as the use of PARP inhibitors, which are known to be toxic to *BRCA1* mutant cells ([@R14]; [@R29]; [@R63]; [@R91]; [@R96]). *FUBP1-*null MCF10F cells also express a variant form of MAGI3, *MAGI3*^*pPA*^, which we previously showed codes for an active oncoprotein that inhibits its full-length form ([@R64]). When present in excess, MAGI3^pPA^ binds MAGI3^FL^ and promotes the nuclear translocation of YAP, a Hippo pathway transcription factor that drives tissue overgrowth and malignant transformation. The MAGI3^pPA^ variant is recurrent and physiologically relevant in human breast cancers because it occurs in 7.2% of primary breast tumors ([@R64]). We also identified that *FUBP1-*null cells generate an aberrant form of *CASP8* mRNA that is noncoding, resulting in loss of CASP8 protein. Dysregulated apoptosis is a classic hallmark of human cancer ([@R26]), so the implications of losing a regulator of apoptosis are widespread. In breast cancer, especially, loss of *CASP8* has been shown to contribute to tumorigenicity and correlates with unfavorable outcomes ([@R62]; [@R72]; [@R97]). As a tumor suppressor, FUBP1 acts analogously to classical epigenetic TGSs that alter the overall architecture of the transcriptional landscape. In this case, however, FUBP1 alters the post-transcriptional landscape in a profound manner to cooperate to drive tumorigenesis.

Although *FUBP1* loss led to cell-type-specific AS of target genes, we observed that 8.5% of FUBP1-target genes are conserved among the AS events in both mammary epithelium and brain. This frequency is similar to the rate of FUBP1-target genes conserved between siFUBP1-U87MG cell line and primary glioma tumors with *FUBP1* LoF (7.1%). As such, this suggests that the loss of *FUBP1* results in consistent and generalizable AS changes across different tissue types but also shows profound tissue-specific differences. Further studies are needed to understand the significance of individual FUBP1-regulated AS events to tumorigenesis in a tumor- and tissue-specific manner.

In addition, we demonstrated that *FUBP1* co-immunoprecipitates with members of the m^6^A complex and that *FUBP1* loss results in decreased m^6^A levels. In parallel with these findings, we commissioned previously published m^6^A-seq databases to identify enrichment of m^6^A levels in exons directly upstream of FUBP1-regulated AS sites. Based on our results, we propose a mechanism for FUBP1 in cancer: through binding RBM15 and VIRMA, FUBP1 helps to recruit the rest of the methyltransferase complex to allow for m^6^A deposition on intended RNA sites ([Figure 5C](#F5){ref-type="fig"}). Because of *FUBP1* loss, there are fewer m^6^A modifications, thus preventing the interaction of normal m^6^A-binding proteins with modified sites and their downstream effects, i.e., AS of cancer driver genes ([Figure 5D](#F5){ref-type="fig"}). In addition, we found that several members of the m^6^A complex, including FUBP1 binding partners, are altered in human breast cancer. Although, individually, these are also rarely mutated and represent LT genes, collectively, they represent a significant genetic alteration that is present across many breast cancers at rates comparable to major drivers. The consequences of these copy number alterations with respect to tumorigenesis will need to be explored in the future.

In sum, our findings demonstrate *FUBP1* loss significantly alters a large collection of genes that contribute to cancer pathogenesis. We have identified *FUBP1* to be an LT driver of breast cancer and have shown that manipulating it alone has powerful implications for the role of AS factors as the gatekeepers to the hallmarks of cancer. Our analyses suggest that genes involved in AS encompass an underappreciated mechanism of oncogenic transformation, and with deeper understanding of their targets and role in cancer, such genes might represent prominent clinical targets.

STAR★METHODS {#S9}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Charlotte Kuperwasser (<charlotte.kuperwasser@tufts.edu>). Plasmids and cell lines generated in this study are available upon request via a material transfer agreement (MTA).

EXPERIMENTAL MODELS AND SUBJECT DETAILS {#S11}
---------------------------------------

### Cell Lines and Tissue Culture {#S12}

The cell lines used in this study (MCF10F, MCF10A and HEK293T) were purchased from ATCC, are originally derived from female tissue (Manassas, VA), and have been authenticated by shorten tandem repeat DNA profiling and validation that they are free of mycoplasma contamination. Cells were grown at 37°C with 5% CO~2~ and cultured in DMEM/F12 supplemented with 5% horse serum, 100 ng/ml cholera toxin, 5 μg/ml insulin, 0.5 μg/ml hydrocortisone, 50 ng/ml EGF, and 1% antibiotic/antimycotic (Corning, Corning, NY). Transfections were performed using FuGENE HD (Promega, Madison, WI). For lentivirus production, HEK293T cells were co-transfected with pCMV-VSV-G, pCMV-D8.2-Δvpr, and lentiviral expression vectors. For the generation of cell lines, MCF10F, MCF10A and HEK293T cells were incubated overnight in viral supernatants supplemented with 8 μl/ml protamine sulfate and subsequently selected for with antibiotics. Cell lines harboring multiple genetic manipulations were created by serial transductions. Clonal cell populations were created from single cells sorted into 96-well plates.

### Mice and Orthotopic Tumor Growth Studies {#S13}

A colony of immunocompromised NOD-SCID mice (RRID: IMSUR_JAX:001303) was maintained in-house under aseptic sterile conditions. Mice were administered autoclaved food and water *ad libitum*. Surgeries were performed under sterile conditions, and animals received analgesic subcutaneously before surgical procedures and antibiotics in the drinking water up to 2 weeks after all surgical procedures. Before surgery, 6-week old female NOD-SCID mice were anesthetized by isoflurane vapor. An incision was made along the right and left flanks to expose the inguinal mammary glands, and cells were injected in a total volume of 30 μL 1:1 Matrigel:phosphate-buffered saline were injected into the gland. Post-operative analgesic, antibiotic and monitoring were provided. Animals were sacrificed when tumors reached burden limit (\~2 cm), and tumors were dissected and measured. In experiments in which injected cells expressed luciferin, cell dissemination was monitored weekly using an IVIS Spectrum (PerkinElmer, Waltham, MA). Image acquisition was performed 5 minutes after intraperitoneal injection of 75 mg/kg D-Luciferin (Gold Biotechnology, St. Louis, MO) with mice dorsal side up. The signals were quantified using the LivingImage software (PerkinElmer) by drawing a region of interest around each mammary gland to determine the radiance (in photons) emitted for a given time.

METHOD DETAILS {#S14}
--------------

### CRISPR-Cas9 Tumor Suppressor Library Screen {#S15}

DNA oligonucleotides encoding sgRNA sequences designed to target the top 100 TUSON-predicted TSGs were synthesized on a custom microarray (Agilent). These oligonucleotides were PCR-amplified separately with specific sets of primers. PCR-amplified gRNA libraries were digested with BbsI and purified on a 10% TBE PAGE gel. Purified, digested fragments were cloned into BsmBI-digested pLentiCRISPRv2 (Addgene Plasmid \#52961). A negative control non-cutting gRNA library comprised of 500 gRNAs targeting the *E. coli* genome was designed and cloned in parallel. Gel purified digestion products were cloned into a XhoI/EcoRI digested pHAGE-pInducer10-miRE-pheS(ΔEcoRI) plasmid. To create the pHAGE-pInducer10miRE-pheS(ΔEcoRI) vector, the pInducer10 mir30 shRNA construct was moved to the pHAGE backbone, with pertinent mir30 elements being replaced by miR-E elements by PCR. In addition, the sole EcoRI restriction site in the pHAGE backbone was mutated to facilitate cloning. To produce lentivirus, HEK293T cells were seeded in tissue culture dishes at 6×10^5^ cells per 0.9 cm^2^ of tissue culture surface area. Plasmid DNA was diluted into serum-free medium with a lentiviral packaging plasmid mixture of SV40 VSVg, Gag/Pol, Tat, and Rev, and transfected with PolyJet (SignaGen). Cell culture media was changed 24 hours later. After 48 hours, the supernatant was harvested, filtered through a low-protein-binding HT Tuffryn® membrane with 0.45 μm pores (Pall, cat \#4184), aliquoted, and stored at −80°C. Lentiviral titer was determined by transducing U2-OS cells plated at clonogenic density with serial dilutions of virus in the presence of 4 μg/mL polybrene. After selecting with puromycin, colonies were stained with methylene blue and counted manually to determine viral titer.

MCF10F cells were incubated overnight with the lentiviral libraries, at a multiplicity of infection (MOI) of 3 viral particles per cell. After 24 hours, the media was replaced with regular growth media, and the following day the library-infected cells were selected with puromycin. Surviving cells were expanded over 7 days. A fraction of cells, a "pre-screen pellet" for analyses of library representation in the cells pre-injection, was set aside and frozen, and the remaining cells were used for orthotopic xenografts, in which 1\*10^6^ cells were injected per gland. Tumors grew over a span of 10 weeks, at the end of which animals were sacrificed. Tumors larger than 5 cm^3^ were randomly sampled for histology, and the remainder of the tumor was digested and processed for sequencing. If the tumor was smaller than 5 cm^3^, it was entirely used for sequencing. Tumors were manually diced with a razor blade: for histology, sections were fixed in 10% neutral buffered formalin for 24 hours before storage in 70% ethanol prior to paraffin embedding and sectioning. Remaining parts of tumors were digested overnight at 55°C in 10mM Tris pH 8.0, 10mM EDTA, 0.5% SDS, and 0.5mg/mL Proteinase K. Subsequently, genomic DNA was isolated by two rounds of phenol: chloroform extraction using Phaselock tubes (5 PRIME), followed by two rounds of chloroform extraction. RNase A was added at a final concentration of 25 μg/mL and incubated for at least 4 hours at 37°C before two additional rounds of phenol: chloroform and one additional round of chloroform extraction. DNA was ethanol-precipitated, recovered by centrifugation, washed three times with 70% ethanol, and resuspended in 10mM Tris-Cl pH 8.5. sgRNA sequences were PCR-amplified and adapted for Illumina sequencing. This adaptation involved the addition of a P5 adaptor and a stagger sequence of variable length 5′ to the variable sgRNA, followed by a 3′ Illumina index sequence primer binding site, a 7 base pair index sequence, and a P7 adaptor. The relative representation of library sgRNA in each sample was determined by Illumina sequencing on a HiSeq2000 system.

To identify the cooperating TSGs promoting tumor growth, we recovered the barcoded sgRNAs from genomic DNA via PCR, followed by high-throughput sequencing of the PCR amplicons. An enrichment score for each gRNA was calculated by dividing the number of reads for each TSG in the screened cells by that of the pre-screen cells (transduced but not injected cells) and of cells that were transduced with non-targeting sgRNAs (control). The sgRNAs in cooperative subclones were grouped together based on read count similarity. The differences in read counts were calculated, and a cluster of two or more sgRNAs with very small differences followed by a steep drop off indicated a higher likelihood that the sgRNAs appeared in the same tumor subclone.

### Cellular proliferation and soft agar assays {#S16}

To measure cellular proliferation, 200 cells were plated per well in a 96-well plate, and after 2 days, cell viability was measured using CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) every day for the following week. Colorimetric readout was measured on a SpectraMax (San Jose, CA) plate reader. For soft agar assay to detect anchorage independent growth, 1\*10^4^ cells were suspended in a 0.4% Seaplaque (Lonza, Basel, Switzerland) agarose:culture media mixture and layered onto a 0.8% agarose in DMEM. Fresh growth medium was applied every 7 days and colonies were allowed to grow for 2 weeks. Colonies were stained with 0.005% crystal violet and imaged for quantification (colonies ≥ 50 μm) with Fiji ImageJ software.

### 3D Hydrogel Seeding and Analyses {#S17}

Protocol for seeding of hydrogels (750 cells per gel) and immunofluorescence staining was followed as previously described ([@R60]; [@R83]). Fixed, permeabilized, and stained gels were mounted on glass slides and coverslipped, and images were acquired on a Zeiss 510 confocal microscope. Confocal images were first processed to adjust color palette, balance, and contrast using the Fiji ImageJ software applied to the entire image before figure assembly in Adobe Illustrator.

### Protein isolation for immunoblotting, immunoprecipitation, and mass spectrometry {#S18}

To isolate protein from whole-cell lysates for immunoblotting, cells were scraped and lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA) supplemented with protease inhibitors (Roche, Boston, MA) and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). Protein samples were separated by SDS-PAGE according to standard procedures, transferred onto nitrocellulose membranes and blocked with 5% milk in Tris-buffered saline, 0.05% Tween-20. Immunoblotting was performed according to standard procedures and protein detection was visualized using enhanced chemiluminescence (Thermo Fisher Scientific). For immunoprecipitation for detecting FUBP1-interacting proteins, HEK293T cells were stably transfected with a pLenti6.2/V5-DEST expression vector containing full-length FUBP1, kindly gifted to us from the La Baer lab (Arizona State University). Control cells were transfected with an empty vector pLenti6.2/V5-DEST lentivirus (ThermoFisher). Cells were selected for blasticydin resistance and cellular lysates were pre-blocked with Protein A Magnetic Beads (Pierce, Waltham, MA) and subsequently incubated with anti-V5 antibody. Protein A Magnetic Beads were used to immunoprecipitate V5-bound proteins, and samples were eluted in NuPAGE LDS Sample Buffer (Thermofisher Scientific, Waltham, MA), followed by SDS-PAGE and standard immunoblotting procedure. For protein mass spectrometry to identify FUBP1-interacting proteins, FUBP1-V5 IP and empty vector (EV)-V5 lysates were separated by SDS-PAGE, fixed in the gel, stained with a 0.3% Coomassie Blue R250 solution, then destained overnight. Large (50--250kD), medium (30--50kD) and small (10--30kD) bands were excised, digested, and analyzed by liquid chromatography-tandem-mass spectrometry (Taplin Mass Spectrometry Facility, Harvard Medical School). The accepted list of interacting proteins was obtained by subtracting common contaminants (CRAPome), and only including proteins that uniquely appeared with ≥ 6 unique peptides in at least 2/3 experiments, compared to empty vector control.

### Dot blot assays, and m^6^A IP-IB assays {#S19}

For dot blot assays, poly(A) RNA was purified from total RNA using DynaBeads mRNA Purification Kit (ThermoFisher, Waltham, MA). Poly(A) RNA was serially diluted to 180 ng/μl, 45 ng/μl, 11.25 ng/μl. Each dilution was dotted (2.5ml) on a BrightStar-Plus positively charged nylon membrane (Invitrogen, Carlsbad, CA) in duplicate. The poly(A) RNA was crosslinked to the membrane in a Stratalinker 2400 Crosslinker twice (1,200 μJ) and the membrane was washed for 5 min in wash buffer (PBS, 0.02% Tween-20) before blocking for 1 hr (PBS, 5% Milk, 0.02% Tween-20). The membrane was incubated overnight at 4°C in polyclonal rabbit anti-m^6^A antibody diluted in blocking buffer. Treatment with secondary antibody was performed according to standard immunoblotting procedures and m^6^A detection was visualized using enhanced chemiluminescence. Levels of m^6^A were quantified by measuring density of dots using Fiji ImageJ. To immunoprecipitate proteins that bind m^6^A-modified and unmodified RNA, protocol was followed as described by [@R16]. Samples were separated by SDS-PAGE and immunoblotting by standard procedures followed.

### RNA isolation and RNA-seq {#S20}

Total RNA was extracted using the MiRNeasy Maxi Kit (QIAGEN). Sequencing libraries were prepared using the TruSeq Stranded mRNA kit and samples were sequenced by the Illumina HiSeq 2500 system. For paired end sequencing, the Rapid PE150 flow cell was used.

### m^6^A-RIP qPCR {#S21}

Poly(A) RNA was purified from total RNA using DynaBeads mRNA Purification Kit (ThermoFisher Scientific). Poly(A) RNA was fragmented using the NEBNext Magnesium RNA Fragmentation Module (NEB) according to manufacturer's protocol. The fragmentation reaction was stopped with 50 mM Fragmentation Stop Solution (NEB) and one round of ethanol precipitation was used for RNA cleanup: fragmented RNA was combined with sodium acetate, linear acrylamide, and 100% ethanol. Fragmented poly(A) RNA was incubated with 1 μl EpiMark anti-m^6^A antibody (NEB) pre-bound to pre-washed Protein G magnetic beads (NEB) in reaction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40). m^6^A-bound beads were washed twice in reaction buffer, then twice in low salt reaction buffer (50 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40) and then two washes in high salt reaction buffer (500 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40). Immunoprecipitated RNA was eluted in 30 μl Buffer RLT (QIAGEN), then cleaned and concentrated with Dynabeads MyOne Silane (ThermoFisher) according to manufacturer's protocol. Bound RNA was eluted in DEPC water and used for first-strand cDNA synthesis using ProtoScript II First Strand cDNA Synthesis Kit (NEB). cDNA was also generated from total RNA, representing the input for the RIP.

Three-step qPCR amplification was performed using SYBR Green Supermix (BioRad) on a CFX96 Real-time Thermal Cycler (BioRad). Threshold cycle numbers were converted to relative gene expression values using the 2^−ΔΔCt^ method.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S22}
---------------------------------------

### RNA-Seq Analyses {#S23}

Raw sequencing data were aligned using RSEM using a human hg38 library and differential expression was performed with EBSeq ([@R43]; [@R43]). STAR ([@R15]) was used to align raw seq files with the most current reference human genome (hg38). To identify differential alternative splicing events between the control and FUBP1 null samples tested, STAR output was then used to run rMATS4.0.1 ([@R81]), which generated 5 individual output files that annotated and statistically analyzed the five different kinds of splicing events (A5SS, A3SS, SE, MXE, and RI). Only splicing events with a p value \< 0.001 were considered statistically significant. Sashimi plots were generated using rmats2sashimiplot (<https://github.com/Xinglab/rmats2sashimiplot>).

EBSeq output was used for functional clustering and universal gene enrichment analyses of differentially expressed genes in sequenced sgNTC and sgFUBP1 RNA. The R package clusterProfiler ([@R98], [@R99]) was used with the MSigDB collection of annotated gene sets ([@R43]) to detect the most significantly enriched functions among the gene list of interest, which contained the top up and downregulated (FDR ≤ 0.05, log2 fold change ≥ j1.5) genes between the sgNTC and sgFUBP1 samples. GO and KEGG annotation data for *Homo sapiens* was downloaded from the R package Bioconductor ([@R23]; [@R34]) and the groupGO function in clusterProfiler was used to functionally cluster the gene list. Gene Set Enrichment Analysis (GSEA) ([@R85]) was performed with the same gene list that was used for clusterProfiler, generated in a ranked .rnk format.

For bioinformatic analysis and identification of putative m^6^A peaks, sequence data were downloaded from the Gene Expression Omnibus (GEO), dataset GSE37005. Alignment data were obtained by following a previously published protocol for m^6^A-Seq analysis ([@R17]).

### Clinical Data Analysis {#S24}

For detection of alteration frequency of *FUBP1* and other hits from the screen across various human cancers, all 233 studies in cBioPortal ([cbioportal.org](http://cbioportal.org)) encompassing 69,310 samples were used. For analysis of alteration frequency of *FUBP1* and other m^6^A regulators in breast cancer, the METABRIC Nature Communications study encompassing 2,509 breast invasive carcinoma samples was selected ([@R70]) and the indicated genes were searched for detection of frequency of copy number and mRNA level alterations.

### Statistical Analysis {#S25}

The data are presented as mean and SEM from n cells or animals. Comparisons between two groups were performed using a t test. Analyses with three or more groups were performed with a one-way or two-way analysis of variance (ANOVA). Data were analyzed and compared between groups with GraphPad Prism (GraphPad Software, Inc) versions 7 and 8. p \< 0.05 was considered statistically significant.

DATA AND CODE AVAILABILITY {#S26}
--------------------------

The accession number for the RNA-seq data reported in this paper is GEO: GSE122416. Raw IP/MS data are shown in [Table S2](#SD3){ref-type="supplementary-material"}.
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![Identification of Cooperating TSGs in an *In vivo* Loss-of-Function CRISPR-Cas9 Screen\
(A) Experimental schema for CRISPR-Cas9 library *in vivo* screen for cooperating TSGs. The library was packaged in lentivirus used to infect MCF10F cells at an MOI = 3. Cells were selected for expression of the library and implanted into NOD-SCID mammary fat pads at 1 × 10^6^ cells per gland. Tumors were excised and sequenced for analyses.\
(B) H&E staining of tumors for identification of histological phenotypes: squamous (i and v), metaplastic (ii), papillary (iii and vi), and adenocarcinoma (iv).\
(C) Immunohistochemistry (IHC) staining of tumors for identification of specific epithelial and proliferation markers: EpCAM (i), Ki67 (ii), PR(203) (iii), PR(403) (iv), E-cadherin (v), p53 (vi). Scale bars represent 100 μm. Magnification = 203 for microscope images.\
(D) Pie charts representing the clonal heterogeneity and dominant contributing and/or cooperating TSGs in the tumors. Each chart represents one tumor; each slice of each pie chart represents a subclone.\
(E) Mutual exclusivity analysis of *FUBP1* (gene A) and tumor suppressor genes that cooperated with *FUBP1* in the screen (gene B) across 69,310 human cancer samples in 233 studies using cBioPortal. "Neither" represents the number of samples in which neither gene A nor B was altered. "A" represents the number of samples in which only gene A is altered. "B" represents the number of samples in which only gene B was altered. "A&B" represents the number of samples in which both genes A and B were altered.](nihms-1543630-f0002){#F1}

![*FUBP1* Loss Drives Several Characteristic Features of Transformation and, with PTEN Loss, Promotes Tumor Growth *In vivo*\
(A) Western blot of lysates from MCF10F cells transduced with NTC, PTEN, FUBP1, or PTEN+FUBP1 CRISPR-Cas9 sgRNA to show knockout of corresponding genes.\
(B) Proliferation of the indicated cell lines over 7 days, measured by MTS assay, analyzed with an ANOVA with a multiple-comparisons test.\
(C) Soft agar growth assays for the indicated cell lines. Images show representative soft agar fields for the indicated cell lines after 2 weeks. Scale bar represents 50 μm. Analyzed with one-way ANOVA with a multiple comparisons test against sgNTC.\
(D) Quantification of soft agar colonies in the indicated cell lines after 2 weeks.\
(E) Representative immunofluorescent (IF) images of the indicated cell lines after 10 days in hydrogels. Green, CK14^+^; red, CK8/18^+^. Nuclei stained with Hoechst (blue). Scale bars represent 100 μm. Pie charts represent quantification of 3D tissue morphology, cellular polarity, and expression. Blue sections represent T1 structures, red represent T2, green represent T3, and white represent T4.\
(F) Bioluminescence imaging was used to detect tumor growth in NOD-SCID mice injected with the indicated cell lines (n = 5 mice per cell line, 5 × 10^6^ cells injected per gland).\
(G) Quantification of bioluminescence emitted from each injected gland at 2 weeks after injection.\
(H) Gross and microscopic detection of tumor growth in NOD-SCID gland injected with *PTEN*/*FUBP1-*null MCF10F cells. Images depict highly vascularized tumors (i) with angiogenesis and inflammation (ii and iii), as well as an abnormally mitotic cell (iv). Scale bars represent 50 μm. Data are presented as means ± SEM, n = 3 biological replicates per cell line. \*p \< 0.05, \*\*\*p \< 0.0005 (two-tailed Student's t tests unless otherwise indicated).](nihms-1543630-f0003){#F2}

![*FUBP1* Promotes Alternative Splicing of Cancer Driver Genes\
(A) rMATS 4.0.1 used for detection of alternative splicing events in *FUBP1-*null cells. Pie chart shows distribution of A5′-splice site (A5SS), A3′-splice site (A3SS), skipped exon (SE), retained intron (RI), and mutually exclusive exon (MXE) splice events.\
(B) Enrichment of functions of alternatively spliced genes detected by rMATS, performed by DAVID functional annotation analysis.\
(C) Summary of cancer genes that are alternatively spliced in *FUBP1-*null cells, indicating gene name, biotype, and summary of function.\
(D--F) Western blots of NTC and *FUBP1*-null cell lysates for CASP8 (D), BRCA1 (E), and MAGI3 (F) and corresponding sashimi plot of alternative splicing. Blot for BRCA1 was stripped and re-probed for MAGI3. In sashimi plots, y axis represents a modified reads per kilobase of transcript (RPKM), per a million mapped reads. Peaks report number of junction reads. Below each, cartoon representations of alternative isoforms: exons and introns are not drawn to scale and represented as black rectangles and lines, respectively.](nihms-1543630-f0004){#F3}

![Exons Upstream of *FUBP1*-Regulated Splice Sites Exhibit Diminished m^6^A Levels in *FUBP1*-Null Cells\
(A) Western blot validation of significant proteins from IP/MS experiment.\
(B and C) Dot blot measuring global m^6^A levels in mRNA of indicated cell lines (B), quantified in (C).\
(D) RNA-IP with m^6^A-modified or non-modified RNA bait followed by immunoblotting for a *bona fide* m^6^A reader, YTHDF2, and FUBP1.\
(E) Distribution of m^6^A-seq peaks across the *CASP8*, *BRCA1*, and *MAGI3* loci, based on analysis of previously published m^6^A-seq data in HepG2 cells. The locations of the putative m^6^A sites are indicated within exons directly upstream of splice sites yielding AS transcripts found in *FUBP1-*null cells.\
(F) Relative m^6^A levels at m^6^A consensus sites of *CASP8*, *BRCA1*, and *MAGI3* in exons upstream of splice sites that yield alternative variants, determined by m^6^A RIP-qPCR in NTC and *FUBP1*-null MCF10F cells.\
(G) *CASP8*, *BRCA1*, and *MAGI3* mRNA levels relative to *GAPDH* determined by quantitative real-time PCR in NTC and *FUBP1*-null MCF10F cells (n = 2) using primers flanking the regions distal from splice sites, not surrounding m^6^A consensus sites. Data are presented as means ± SEM, n = 3 biological replicates per cell line. \*p \< 0.05 (two-tailed Student's t tests), unless otherwise stated.](nihms-1543630-f0005){#F4}

![*FUBP1* and Other m^6^A-Associated Proteins that Are Altered in Human Breast Cancers\
(A and B) Percentage of breast cancer samples with (A) low (left) or high (right) copy number or mRNA alterations in FUBP1 or (B) other m^6^A-related genes, reported by METABRIC (2,509 samples).\
(C and D) Schematic representation of FUBP1 mechanism in regulating alternative splicing: FUBP1 binds VIRMA and RBM15 to help recruit the rest of the m^6^A complex to target mRNA sites that affect splicing of cancer drivers (C). In the context of FUBP1 loss (D), there are fewer m^6^A modifications, thus preventing the interaction of normal m^6^A-binding proteins with modified sites and their downstream effects, i.e., AS of cancer driver genes.](nihms-1543630-f0006){#F5}

###### 

Co-occurring sgRNAs Identified in Tumor Subclones

               Tumor 1                  Tumor 2                Tumor 3              Tumor 4                Tumor 5               Tumor 6
  ------------ ------------------------ ---------------------- -------------------- ---------------------- --------------------- --------------------------
  Subclone 1   FUBP1, PTEN              PTEN, KDM5C            FUBP1, PTEN          PTEN, ARID1B           SMAD4, PTEN           NF2, SMARCB1, GATA3, RB1
  Subclone 2   PTEN, NF2                MLLT4, ACVR1B          PTEN, PIK3R1, TP53   PTEN, RASA1            PTEN, CDKN2A          SMAD4, PTEN
  Subclone 3   FUBP1, TP53, CDH1        ZNF318, NF2            PTEN, NCOR1          STAG2, SMARCB1, PTEN   PIK3R1, NF2           WT1, GATA3, RUNX1
  Subclone 4   ATM,SMAD4                GATA3, CDKN1A          RB, PTEN, FUBP1      KDM5C                  BAP1, RASA1, TRIP12   SMAD2, TRIP12, ZNF318
  Subclone 5   NF2, PIK3R1              APC, RNP43             RNX1, MLLT4          KDM6A, ZNF318          HLA-B, RBM10          NF2, TGFBP2
  Subclone 6   CDKN2A1, TGFBR2, DMK5C   CRIPAK, ASXL1, AJUBA   TRIP12, ZNF318       FBXW7, TP53, PTEN                            SMARCA4, ARHGAP35
  Subclone 7   CREBBP, STK11, SMAD4                            FUBP, KDM5C, PTEN    PIK3R1, MLLT4, NCOR1                         ARID2, RB1

###### 

FUBP1 Splicing Targets Conserved across Breast and Brain

  Splice Event   Gene Names
  -------------- ----------------------------------------------------------------------------------
  A3SS           SLC43A3, FUS, ZBED5, RESP1, KIAA1529, ABI2
  A5SS           C6orf48, TPM1, IARS, SEC31A, FASTK, SLC43A3, ITF81, KCNK2, SKA2, ALDH18A1, UBAP2
  SE             MYL6, FUS, MYL6B, CAPN2, UBC, SCARB1, DALRD3, FAM72D, BATS
  RI             None
  MXE            Data Not Available

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                   SOURCE                   IDENTIFIER
  ------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------
  Antibodies                                                                                                     
  Mouse monoclonal: β-actin                                                             Abcam                    Cat\# ab6276; RRID: AB_2223210
  Rabbit polyclonal: m^6^A                                                              Synaptic Systems         Cat\# 202--003; RRID: AB_2279214
  Rabbit monoclonal: FUBP1                                                              Abcam                    Cat\# ab181111; EPR12327
  Rabbit monoclonal: PTEN                                                               Cell Signaling           Cat\# 9559; RRID: AB_390810
  Mouse monoclonal: V5                                                                  Thermofisher             Cat\# R960--25; RRID: AB_2556564
  Rabbit polyclonal: MATR3                                                              Bethyl Labs              Cat\# A300--591A; RRID: AB_495514
  Rabbit polyclonal: RBM15                                                              Abcam                    Cat\# ab96544; RRID: AB_10680900
  Rabbit monoclonal: HuR                                                                Cell Signaling           Cat\# 12582S; D9W7E
  Rabbit polyclonal: hnRNPA2B1                                                          Thermofisher             Cat\# PA5--30061; RRID: AB_2547535
  Rabbit polyclonal: METTL3                                                             Fisher                   Cat\# 15073--1AP; RRID: AB_2142033
  Rabbit polyclonal: YTHDF2                                                             Abcam                    Cat\# ab99080; RRID: AB_10675362
  Rabbit polyclonal: CK14                                                               Vector Labs              Cat\# 9020-P; RRID: AB_149727
  Mouse monoclonal: CK8/18                                                              Thermofisher             Cat\# MA5 12281; RRID: AB_10986863
  Rabbit polyclonal: VIRMA                                                              Bethyl Labs              Cat\# A302--123A; RRID: AB_1720420
  Rabbit polyclonal: CASP8                                                              Genetex                  Cat\# GTX110723; RRID: AB_2036448
  Rabbit polyclonal: BRCA1                                                              Santa Cruz               Cat\# sc-642; RRID: AB_630944
  Rabbit polyclonal: MAGI3                                                              Novus Biologicals        Cat\# NBP2--17210
  Mouse: AF555-                                                                         Thermofisher             Cat\# A21424; RRID: AB_141780
  Rabbit: AF488-                                                                        Thermofisher             Cat\# R37116; RRID: AB_2556544
  Mouse: HRP-                                                                           Cell Signaling           Cat\# 7076; RRID: AB_330924
  Rabbit: HRP-                                                                          Cell Signaling           Cat\# 7074; RRID: AB_2099233
  Mouse monoclonal: MDM2                                                                Santa cruz               Cat\# sc-965; RRID: AB_627920
  Rabbit monoclonal: CASP8                                                              Abcam                    Cat\#ab32125; RRID: AB_2068469
  Rabbit monoclonal: FUBP1                                                              Abcam                    Cat\#ab213525; EPR19208
  Bacterial and Virus Strains                                                                                    
  pLentiCRISPRv2-blast                                                                  Addgene                  RRID: Addgene_83480
  pLentiCRISPRv2-puro                                                                   Addgene                  RRID: Addgene_52961
  pLenti6.2/V5-DEST-FUBP1                                                               DNASU Repository         HsCD00329438
  pLenti6.2/V5-DEST Empty Vector                                                        ThermoFisher             V36820
  pLenti-PGK V5-LUC Neo                                                                 Addgene                  RRID: Addgene_21471
  pHAGE-pInducer10-miRE-pheS(ΔEcoRI)                                                    Elledge Lab              RRID: Addgene_44011
  One shot Stbl3 competent *E. coli*                                                    ThermoFisher             C737303
  Critical Commercial Assays                                                                                     
  CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS)                     Promega                  G3582
  TruSeq mRNA Stranded Library Prep                                                     Illumina                 20020594
  NEBNext Magnesium RNA Fragmentation Module                                            NEB                      E6150S
  DynaBeads mRNA Purification Kit                                                       ThermoFisher             61006
  DynaBeads MyOne Silane                                                                ThermoFisher             37002D
  protoScript II First Strand cDNA Synthesis Kit                                        NEB                      E6360S
  Deposited Data                                                                                                 
  Raw and analyzed RNaseq data                                                          This paper               GEO: GSE122416
  FUBP1-V5 and Empty Vector-V5 Immunoprecipitation/Mass spectrometry data               This paper               [Table S3](#SD4){ref-type="supplementary-material"}
  m^6^A Seq data                                                                        [@R16]                   GEO: GSE37005
  Experimental Models: Cell Lines                                                                                
  Human: MCF10F cells                                                                   ATCC                     Cat\# CRL-10318; RRID: CVCL_3633
  Human: MCF10A cells                                                                   ATCC                     Cat\#CRL-10317; RRID: CVCL_0598
  Mouse: HEK293T cells                                                                  ATCC                     Cat\# CRL-3216; RRID: CVCL_0063
  Experimental Models: Organisms/Strains                                                                         
  Mouse: NOD.CB17-*Prkdc*^*scid*^/J                                                     The Jackson Laboratory   Cat\# 001303; RRID: IMSR_JAX:001303
  Oligonucleotides                                                                                               
  Primers for m6A RIP-qPCR: See [Table S4](#SD5){ref-type="supplementary-material"}     This paper               [Table S4](#SD5){ref-type="supplementary-material"}
  sgRNA for FUBP1.3: GTTTGCTGCTGATGCATCGG                                               This paper               N/A
  sgRNA for FUBP1.10: GCAGCCCCATATGCTCCCCA                                              This paper               N/A
  sgRNA for PTEN: GCATCTGGATTATAGACCAG                                                  This paper               N/A
  Methylated RNA bait: biotin-AUGGGCCGUUCAUCUGCU AAAAGG-m6A- CUGCUUUUGGGGCUUGU          [@R16]                   N/A
  Non-methylated RNA bait for RIP: biotin-AUGGGCCGUU CAUCUGCUAAAAGGACUGCUUUUGGGGCUUGU   [@R16]                   N/A
  Recombinant DNA                                                                                                
  Plasmid: pLentiCRISPRv2-blast-FUBP1.3                                                 This paper               N/A
  Plasmid: pLentiCRISPRv2-blast-FUBP1.10                                                This paper               N/A
  Plasmid: pLentiCRISPRv2-puro-PTEN                                                     This paper               N/A
  Plasmid: pLenti6.2/V5-DEST-FUBP1                                                      DNASU Repository         HsCD00329438
  Plasmid: pLenti-PGK V5-LUC Neo                                                        [@R7]                    Addgene Plasmid \#21471
  Software and Algorithms                                                                                        
  RSEM                                                                                  [@R45]                   <https://github.com/deweylab/RSEM>
  Samtools                                                                              [@R46]                   <http://samtools.sourceforge.net/>
  EBSeq                                                                                 [@R44]                   <http://bioconductor.org/packages/release/bioc/html/EBSeq.html>
  rMATS.4.0.1                                                                           [@R79], [@R81]; [@R68]   <http://rnaseq-mats.sourceforge.net/>
  Rmats2sashimiplot                                                                     [@R24]                   <https://github.com/Xinglab/rmats2sashimiplot>
  STAR                                                                                  [@R15]                   <https://github.com/alexdobin/STAR>
  ClusterProfiler                                                                       [@R98]                   <http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html>
  Sene Set Enrichment Analysis (GSEA)                                                   [@R85]                   <http://software.broadinstitute.org/gsea/index.jsp>
  Database for Annotation, Visualization, and Integrated Discovery (DAVID)              [@R31]; [@R32]           [https://david.ncifcrf.gov](https://david.ncifcrf.gov/)

###### Highlights

-   A combinatorial CRISPR screen identifies clinically relevant cooperating cancer genes

-   ***FUBP1*** loss cooperates with ***PTEN*** loss to promote tumor growth

-   ***FUBP1***^−*/*−^ cells undergo widespread alternative splicing and reduced m^6^A methylation

-   Loss of one gene can alter the transcriptional landscape to promote tumorigenicity
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